Clinical trials: Moderate COPD, open to volunteers
COPD
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.
- Trial name
- AER-01-002 (NCT06731959)
- Testing
- Flexlamose
- Volunteers
- 100 people
- Sponsor
- Aer Therapeutics
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled…
- Trial name
- ENDURA-1 (NCT06959095)
- Testing
- Depemokimab
- Where
- 281 sites in United States, Argentina and 21 more
- Volunteers
- 981 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- EMBARK (NCT06883305)
- Testing
- Tezepelumab
- Where
- 305 sites in United States, Brazil and 16 more
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
COPD
A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.
- Trial name
- NCT07640451
- Testing
- HRS-9821 Inhalation Suspension
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when…
- Trial name
- RENEW-COPD (NCT07759245)
- Testing
- Brenipatide, Standard of Care
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease
A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Explore the Efficacy and Safety of CM512 Injection in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06980142
- Testing
- CM512
- Volunteers
- 204 people
- Sponsor
- Keymed Biosciences Co.Ltd
COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive…
- Trial name
- NCT07314242
- Testing
- Hemay005 tablets, Roflumilast Oral Tablet
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe…
- Trial name
- NCT07418736
- Testing
- CM326 dose 1, CM326 dose 2
- Where
- China
- Volunteers
- 318 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 Trial of JKN2401 Injection in COPD
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07330310
- Testing
- JKN2401 Injection
- Volunteers
- 888 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
COPD (Chronic Obstructive Pulmonary Disease)
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
- Trial name
- Sirius (NCT07646587)
- Testing
- WIN378
- Where
- 32 sites in United States, Argentina
- Volunteers
- 105 people
- Sponsor
- Windward Bio
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- Trial name
- PRESTO (NCT07082738)
- Testing
- AZD6793
- Where
- 367 sites in United States, Argentina and 22 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD.
- Trial name
- NCT07382258
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Novlead Inc.
COPD
Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection
This is a multicenter, randomized, double-blind, placebo-parallel-controlled, two-stage design, Phase II clinical study. This study is divided into two stages.
- Trial name
- NCT07519499
- Testing
- XKH001Injection
- Volunteers
- 75 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Moderate to Severe Chronic Obstructive Pulmonary Disease
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD.
- Trial name
- COPD (NCT07363694)
- Testing
- PF-07275315 dose 1, PF-07275315-dose 2, PF-07275315-dose 3
- Where
- 189 sites in United States, Argentina and 16 more
- Volunteers
- 1,156 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with…
- Trial name
- ENDURA-2 (NCT06961214)
- Testing
- Depemokimab
- Where
- 193 sites in United States, Argentina and 14 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Chronic Obstructive Pulmonary Disease
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long…
- Trial name
- NCT07839884
- Testing
- Tilrekimig
- Volunteers
- 1,360 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while…
- Trial name
- ENHANCE-3 (NCT07874815)
- Testing
- Ensifentrine, Standard of Care (SOC)
- Volunteers
- 2,136 people
- Sponsor
- Merck Sharp & Dohme LLC
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study of RC1416 Injection in COPD
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07402551
- Testing
- RC1416
- Where
- 46 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.